Reviewed listing: NASDAQ:INCY · Analysis dated Oct 15, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Incyte develops and sells medicines for blood disorders, cancer, and inflammatory skin diseases. The company also receives money from partners that market licensed medicines.
What supports the business?
Incyte is growing even without the large one-time accounting gain: in the second quarter of 2026, drug sales increased by 17% after adjusting for it. The business also generates substantially more cash than it needs for capital expenditures.
What could improve?
Higher sales of Opzelura and newer cancer drugs could reduce dependence on Jakafi. Additional approvals provide further opportunities, but guarantee neither high profits nor rising share prices.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
111.57 USD are conditionally reasonable if the newer drugs continue to succeed, but not clearly cheap. In view of the foreseeable decline in Jakafi, I am not yet convinced by the price-risk relationship.
What is the main risk?
For its most important drug, Jakafi, 2028, critical patent protection expires; cheaper generics could severely affect revenue and earnings. New drugs must first offset this pressure.
What is the overall assessment?
Incyte has a growing, financeable drug business. However, at the specified price of 111.57 USD, timely replacement of Jakafi revenue remains the decisive economic test: a conditionally justifiable price, with an overall stance of watch rather than an already compelling opportunity.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign inSources used in the analysis
- Original source 1 · api-v4.fcsapi.com
- Original source 2 · data.sec.gov
- Original source 3 · investor.incyte.com · Feb 10, 2026
- Original source 4 · investor.incyte.com · Feb 10, 2026
- Original source 5 · investor.incyte.com · Jul 28, 2026
- Original source 6 · www.sec.gov · Jul 28, 2026
- Original source 7 · investor.incyte.com · Apr 28, 2026
- Original source 8 · www.sec.gov · Jul 06, 2026
- Original source 9 · investor.incyte.com · Jul 29, 2026
- Original source 10 · investor.incyte.com · Sep 25, 2026
- Original source 11 · www.sec.gov · Apr 28, 2026
- Original source 12 · investor.incyte.com